Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Serious adverse events (n/N)

Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin detemir (low certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 1.25 [0.76, 2.05]
2 studies · 802 participants
Low

Serious adverse events (n/N)

Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 0.92 [0.58, 1.46]
3 studies · 970 participants
Low